At Fidelta, integrated drug discovery is driven by our determination to deliver efficacious, safe and differentiated preclinical candidates. Our integrated drug discovery platform is built upon:
- Our extensive experience in drug discovery, from target validation to early preclinical development
- A full range of in house drug discovery capabilities including chemistry, pharmacology, ADME, pharmacokinetics and toxicology
- Our therapeutic area expertise, targeting:
- inflammation and linked conditions in the fields of infection, oncology, metabolic disease
- A strong emphasis on translational science, focusing on patients and disease-relevant test models/systems
- Our multidisciplinary team of high-performing bench scientists
Of particular note are the extensive AAALAC accredited in vivo capabilities giving the possibility to take projects all the way to the clinic.